See more : Kesla Oyj (KELAS.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Pharmadrug Inc. (PHRX.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pharmadrug Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Suga International Holdings Limited (0912.HK) Income Statement Analysis – Financial Results
- Bellatora Inc. (ECGR) Income Statement Analysis – Financial Results
- Warburg Pincus Capital Corporation I-B (WPCB-WT) Income Statement Analysis – Financial Results
- ageas SA/NV (AGESY) Income Statement Analysis – Financial Results
- Harbin Pharmaceutical Group Co., Ltd. (600664.SS) Income Statement Analysis – Financial Results
Pharmadrug Inc. (PHRX.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharmadrug.ca
About Pharmadrug Inc.
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 494.99K | 683.67K | 610.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.22K | 2.26K | 394.13K | 501.63K | 357.32K | 0.00 | 0.00 | 110.00 | 275.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -26.22K | -2.26K | 100.86K | 182.04K | 253.26K | 0.00 | 0.00 | -110.00 | -275.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 20.38% | 26.63% | 41.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 226.35K | 712.68K | 553.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 750.69K | 1.68M | 3.39M | 2.88M | 3.40M | 950.53K | 114.07K | 222.79K | 706.58K | 1.25M | 155.12K | 174.86K | 0.00 |
| Selling & Marketing | 357.97K | 0.00 | 0.00 | 0.00 | 0.00 | 207.08K | 4.12K | 0.00 | 0.00 | 0.00 | 3.07K | 3.42K | 0.00 |
| SG&A | 1.11M | 1.68M | 3.39M | 2.88M | 3.40M | 950.53K | 114.07K | 222.79K | 706.58K | 1.25M | 158.19K | 178.28K | 0.00 |
| Other Expenses | 0.00 | 21.03K | 1.28M | 1.14M | 1.95M | 0.00 | 86.00 | 3.64K | 10.05K | 302.59K | 71.94K | 24.38K | 0.00 |
| Operating Expenses | 1.34M | 2.42M | 5.22M | 4.02M | 5.35M | 950.53K | 114.15K | 226.43K | 716.63K | 1.56M | 230.13K | 202.65K | 0.00 |
| Cost & Expenses | 1.34M | 2.42M | 5.62M | 4.52M | 5.70M | 950.53K | 114.15K | 226.43K | 716.63K | 1.56M | 230.13K | 202.65K | 0.00 |
| Interest Income | 334.35 | 0.00 | 0.00 | 30.28K | 0.00 | 0.00 | 0.00 | 324.00 | 3.26K | 10.15K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 223.31K | 156.36K | 351.57K | 476.99K | 188.04K | 75.91K | 1.32K | 2.47K | 888.00 | 606.00 | 357.00 | 0.00 |
| Depreciation & Amortization | 26.22K | 21.03K | 16.02K | 1.30M | 778.23K | 929.87K | 795.26K | 110.00 | 275.00 | 276.00 | 215.00 | 3.14K | 0.00 |
| EBITDA | -1.34M | -2.34M | -4.21M | -4.28M | -5.73M | -2.39M | 681.10K | -7.55M | -711.13K | -2.00M | -538.26K | -202.65K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -772.40% | -368.74% | -706.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.34M | -2.43M | -5.11M | -3.82M | -5.09M | -3.32M | -115.53K | -7.55M | -717.42K | -2.01M | -230.13K | -205.80K | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -1,031.61% | -558.39% | -834.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.94M | -824.15K | -1.49M | -2.06M | -1.89M | -2.58M | -686.00 | -6.46M | 3.26K | -449.21K | -308.95K | 0.00 | 0.00 |
| Income Before Tax | -14.27M | -3.25M | -6.71M | -5.90M | -6.98M | -3.51M | -114.84K | -7.55M | -714.16K | -2.00M | -541.32K | -205.80K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,354.99% | -863.37% | -1,143.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.01M | -190.00K | -833.55K | -389.08K | -442.75K | 2.75M | 1.37K | -40.67K | -317.72K | -264.13K | -133.17K | -8.29K | 0.00 |
| Net Income | -13.20M | -3.06M | -5.87M | -5.51M | -6.54M | -3.89M | -114.84K | -7.51M | -396.44K | -1.74M | -408.16K | -197.51K | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -1,186.60% | -806.46% | -1,070.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.06 | -0.12 | -0.27 | -0.65 | -0.28 | -0.03 | -1.79 | -0.09 | -0.53 | -0.62 | -0.37 | 0.00 |
| EPS Diluted | -0.23 | -0.06 | -0.12 | -0.27 | -0.65 | -0.28 | -0.03 | -1.79 | -0.09 | -0.53 | -0.62 | -0.37 | 0.00 |
| Weighted Avg Shares Out | 56.49M | 50.09M | 47.31M | 20.35M | 10.02M | 13.75M | 3.38M | 4.20M | 4.54M | 3.29M | 655.20K | 530.73K | 144.00K |
| Weighted Avg Shares Out (Dil) | 56.49M | 50.09M | 47.31M | 20.35M | 10.02M | 13.75M | 3.38M | 4.20M | 4.54M | 3.29M | 655.20K | 530.73K | 144.00K |
Source: https://incomestatements.info
Category: Stock Reports